Doptelet (Avatrombopag Tablets)
DOPTELET Rx
Generic Name and Formulations:
Avatrombopag 20mg; tabs.
Company:
Dova Pharmaceuticals
Indications for DOPTELET:
Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Adult:
Start treatment 10–13 days prior to a procedure. Should undergo procedure within 5–8 days after last dose. Take with food. Platelet count (<40 x 109/L): 60mg once daily for 5 days; (40–<50 x 109/L): 40mg once daily for 5 days.
Children:
Not established.
Warnings/Precautions:
Obtain platelet count prior to treatment and on day of procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Do not use to normalize platelet counts. Pregnancy; may cause fetal harm. Nursing mothers: not recommended (during and for ≥2 weeks after last dose).
Pharmacological Class:
Thrombopoietin receptor agonist.
Adverse Reactions:
Pyrexia, abdominal pain, nausea, headache, fatigue, peripheral edema; thrombotic/thromboembolic complications.
Generic Availability:
NO
How Supplied:
Tabs—10, 15
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852 |
